About Integrated BioTherapeutics
Integrated BioTherapeutics (IBT) is an emerging research-based biotechnology company using an integrated multidisciplinary approach for discovery and development of anti-infective vaccines and drugs with an emphasis on emerging infectious disease and biodefense.
Vaccines and Immunotherapeutics for Staphylococcal and Streptococcal Infections
The primary focus of IBT is the development of vaccines and immunotherapeutics for complications resulting from Staphylococcal and Streptococcal infections. Using a portfolio of proprietary recombinant mutant vaccines and vaccine candidates, IBT’s approach targets various toxins produced by these bacteria as key virulence factors that aid the bacteria to evade the immune response and establish persistent or acute infections.
These vaccines and therapeutics are intended for (i) prophylaxis against a biowarfare/bioterror attack, (ii) treatment of staphylococcal and streptococcal toxic shock, and (iii) development of multivalent Staphylococcus vaccines to prevent hospital-acquired infections.
Panfilovirus Vaccine: Ebola & Marburgvirus
Ebola and marburgviruses are among the deadliest viruses known to man and are considered serious biowarfare threats. Using a proprietary technology developed by IBT Founders, IBT is developing a multivalent panfilovirus vaccine for prevention of the deadly hemorrhagic fevers caused by different strains of Ebola and Marburg viruses. This technology is based on virus-like particles, hollow particles that mimic the ebola- or marburgvirus, but are devoid of the viral genetic information. The biggest advantage over other vaccine platforms is that the VLP system is not vector-based, i.e. it does not require another viral system for propagation and efficiency. This will very likely result in a higher efficacy in the population that has antibodies against the vectors of alternative vaccine approaches. The safety profile is also expected to be much better since no "live" virus is present.
Collaborators
